Terminated PHASE2 INTERVENTIONAL 4-arm NCT01998828

Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia

A Phase 2, Open-label, Randomized Study to Evaluate the Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia

Sponsor: Sierra Oncology LLC - a GSK company

Conditions Essential Thrombocythemia Polycythemia Vera

Interventions Momelotinib

Updated 11 times since 2017 Last updated: Apr 14, 2020 Started: Feb 19, 2014 Primary completion: Mar 17, 2015 Completion: May 7, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This trial was terminated. No reason was provided.

Other terminated trials from Sierra Oncology LLC - a GSK company

See all terminations from Sierra Oncology LLC - a GSK company

Other Essential Thrombocythemia trials with similar outcome

Browse all Essential Thrombocythemia trials

This PHASE2 trial investigates Essential Thrombocythemia and Polycythemia Vera and is currently terminated or withdrawn. Sierra Oncology LLC - a GSK company leads this study, which shows 11 recorded versions since 2014 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

11 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE2
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Jul 2023 — Jul 2024 [monthly]

Terminated PHASE2
Apr 2022 — Jul 2023 [monthly]

Terminated PHASE2

▶ Show 6 earlier versions

Jan 2021 — Apr 2022 [monthly]

Terminated PHASE2
May 2020 — Jan 2021 [monthly]

Terminated PHASE2
Mar 2019 — May 2020 [monthly]

Terminated PHASE2
Jun 2018 — Mar 2019 [monthly]

Terminated PHASE2
Feb 2017 — Jun 2018 [monthly]

Terminated PHASE2
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE2

First recorded

Feb 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sierra Oncology LLC - a GSK company

Data source: Sierra Oncology LLC - a GSK company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Dresden, Germany , Frankston, Australia , Houston, United States , La Tronche, France , Minden, Germany , Montreal, Canada , Nantes, France , Paris, France , Parkville, Australia , Scottsdale, United States and 5 more locations